Paradigm Shifts in CAR T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: A Video Viewpoint

Paradigm Shifts in CAR T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma:  A Video Viewpoint

ReachMD Healthcare Image

Join an expert panel as they discuss and evaluate the current treatment landscape for relapsed/refractory large B-cell lymphoma.

Available credits: 0.25

Time to complete: 15 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Since the first chimeric antigen receptor (CAR) T-cell therapy was approved by the US Food and Drug Administration (FDA) for the treatment of large B-cell lymphoma (LBCL) in the third or later line of therapy, there has been significant development in the field. There are now 3 approved CAR T-cell therapies for various subtypes of LBCL, and these immunotherapies are now moving into earlier treatment, with axi-cel and liso-cel both FDA approved in the second-line setting. At the same time, researchers have made tremendous strides in managing the hallmark toxicities of CAR T-cell therapy like cytokine release syndrome (CRS) and neurologic events, opening the possibility for this therapy to move safely beyond academic medical centers and into outpatient settings.

    The educational activity features expert faculty evaluating the current treatment landscape of CAR T-cell therapy for relapsed/refractory LBCL, highlighting evidence set to transform clinical practice particularly in the second-line setting. A three-dimensional mechanism of action animation video clip will illustrate similarities and differences within the structure and costimulatory domains of different CAR T-cell therapies. This activity will serve as the foundation for a robust panel discussion activity entitled Paradigm Shifts in CAR T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: A Video Panel Discussion, where an expert faculty panel will provide their insights on how this new emerging evidence can and should be considered for real-world clinical practice.

  • Disclosure of Relevant Financial Relationships

    Disclosure of Conflicts of Interest
    AXIS Medical Education requires faculty, instructors, authors, planners, directors, managers, reviewers, and other individuals who are in a position to control the content of this activity to disclose all real or apparent conflicts of interest they may have with ineligible companies. An ineligible entity is any organization whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflicts of interest are identified and mitigated prior to initiation of the planning phase for an activity. 

    AXIS has mitigated and disclosed to learners all relevant conflicts of interest disclosed by staff, planners, faculty/authors, peer reviewers, or others in control of content for this activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation or activity. Disclosure information for faculty, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

    The faculty reported the following relevant financial relationships or relationships they have with ineligible companies of any amount during the past 24 months:

    Caron A. Jacobson, MD, reported a financial interest/relationship or affiliation in the form of Consultant: Kile/Gilead; Novartis Pharmaceuticals Corp; BMS/Celgene; Miltenyi; Ipsen Pharmaceuticals; bluebird bio, Inc; Epizyme; Morphosys; AstraZeneca Pharmaceuticals LP; Instil Bio; Abintus Bio; Caribou Bio; and ImmPACT.

    The directors, planners, managers, and reviewers reported the  following financial relationships they have with any ineligible  company of any amount during the past 24 months:  Linda  Gracie-King, MS; Jocelyn Timko, BS; Laura Healy, BS; Marilyn L. Haas-Haseman, PhD, RN, CNS, ANP-BC; Adrienne N. Nedved, MPA, PharmD, BCOP; Melissa Duffy, PA-C ; and Dee Morgillo, MEd, MT(ASCP), CHCP hereby state that they do not have any financial relationships or relationships any ineligible company of any amount during the past 24 months.  Robert Mocharnuk, MD, reported a financial interest/relationship or affiliation in the form of Common stock: Merck of any amount during the past 24 months.

  • Target Audience

    This activity is intended for hematologist-oncologists, medical oncologists, advanced practitioners, and other clinicians involved in the care of patients with relapsed/refractory large B-cell lymphoma.

  • Learning Objectives

    At the conclusion of this activity, participants should be better able to:

    1. Differentiate factors among various CAR T-cell therapies
    2. Identify patients with LBCL with early relapse from or refractory to frontline chemoimmunotherapy, eligible for CAR T-cell therapy
    3. Compare and contrast the trial designs and outcomes for the phase 3 studies TRANSFORM, ZUMA-7, and BELINDA among others such as the phase 2 PILOT trial
  • Accreditation and Credit Designation Statements


    Accreditation Statement

    In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.





    This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.



    Credit Designation for Physicians
    AXIS Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Credit Designation for Physician Assistants

    AXIS Medical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits.  Approval is valid until 2/7/24. PAs should only claim credit commensurate with the extent of their participation.


    Credit Designation for Pharmacists
    This knowledge-based activity is approved for 0.25 contact hour of continuing pharmacy education JA4008106-0000-22-054-H01-P.

    Credit Designation for Nursing
    AXIS Medical Education designates this continuing nursing education activity for 0.25 contact hour.

    Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

    Laboratory Professionals
    This continuing medical laboratory education activity is recognized by the American Society for Clinical Pathology as meeting the criteria for 0.25 CMLE credit. ASCP CMLE credits are acceptable to meet the continuing education requirement for the ASCP Board of Registry Certification Maintenance Program.

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • Provider(s)/Educational Partner(s)

    Provided by AXIS Medical Education.

  • Commercial Support

    This activity is supported by an educational grant from Bristol-Myers Squibb Company.

  • Method of Participation and Request for Credit

    To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately. For pharmacists, your record will be uploaded to CPE Monitor.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments


We’re glad to see you’re enjoying AXISMedEd…
but how about a more personalized experience?

Register for free